change over time and hence are not suitable to reflect the impact of current disease-modifying therapies or changes of disease activity over time. Even for markers that were to show dynamic change related to those factors, the need for sequential lumbar punctures makes their use almost impractical outside of research settings. Hence, the profile of a biomarker for use in routine clinical practice requires (a) accessibility in blood or urine and (b) rapid, quantifiable change in function of disease activity. Until recently, no such biomarker was available. Neurofilaments (Nf) is the first biomarker that may fulfill these premises. A growing number of candidate biomarkers still await reaching this development step.
Nf in MS
There is increasing evidence that neuronal degeneration is a key factor in the pathogenesis of sustained neurological disability in MS and hence may be the main driver for what we call "disease progression". Neuronal degeneration is seen in acute and chronic MS lesions, as well as in extralesional gray and white matter. 2 Several interconnected filaments such as the actin microfilaments (6 nm in diameter), Nf (10 nm), and microtubules (23 nm) are the major proteinic constituents of the axonal cytoskeleton. 3 Nf play an important role in maintaining neuronal size, shape, and axonal caliber. 4 Neurofilament light chain (NfL, 68 kDa) is the most abundant Nf protein and acts as the backbone to which other Nf chains (Nf intermediate chain (150 kDa) and Nf heavy chain (NfH; 190-210 kDa)) bind. Because Nfs are exclusive products of neuronal cells, their key advantage over other biomarkers is their specificity in terms of cellular source, reflection of pathomechanism and hence signal interpretation, that is, they are highly specific for neuronal cell damage and eventual neuronal cell death. Table 1 summarizes many studies that have reported higher levels of NfL in clinically isolated syndrome (CIS) and all stages of MS compared to healthy controls. Noteworthy, increased levels of NfL have been consistently reported in secondary progressive MS (SPMS) 5, 7, 12, 14, [20] [21] [22] and primary progressive MS (PPMS). 5, 7, 14, [20] [21] [22] Similarly, cerebrospinal fluid (CSF) NfL levels are increased in the course of clinical exacerbation (relapse activity). 5, 13, 16, [23] [24] [25] Levels are especially high in patients with a spinal cord relapse, in line with the observation of increased Nf protein concentrations in spinal cord axons, especially the largefiber motor axons of the pyramidal tracts. 7, 26, 27 Moreover, correlations with chronic disability worsening as measured by Expanded Disability Status Scale (EDSS) have been reported in several 5, 7, 11, 28 but not all studies. 12 Besides being a quantitative and real-time measure of disease-related tissue damage, NfL has been found to be as well a drug response marker. Beyond the ability to measure the effect of a specific drug, it is evidence that anti-inflammation by current disease-modifying therapies indeed protects from or reduces neuronal or axonal damage which until now could only be derived indirectly by magnetic resonance imaging (MRI) with brain volume measurements. Table 2 summarizes studies evaluating the effect of disease-modifying treatment on NfL levels. In SPMS 13, 21, 32 and PPMS, 21,32 significant reductions in NfL were observed with natalizumab, 13, 32 mitoxantrone, 21 and rituximab therapy. 21 Of note, after treatment with natalizumab, mitoxantrone, or rituximab, NfL levels in SPMS and PPMS remained significantly higher than in relapsing-remitting MS Teunissen et al. 5 Khalil et al. 6 Kuhle et al. 7 Modvig et al. 8 Hakansson et al. 9 Disanto et al. 10 Relapsingremitting MS Lycke et al. 11 Malmeström et al. 12 Teunissen et al. 5 Gunnarsson et al. 13 Romme et al. 14 Kuhle et al. 15 Novakova et al. 16 Hakansson et al. 9 Kuhle et al. 17 Disanto et al. 18 Piehl et al. 19 Secondary progressive MS Malmeström et al. 12 Norgren et al. 20 Teunissen et al. 5 Romme et al. 14 Kuhle et al. 7 Axelsson et al. 21 Trentini et al. 22 Disanto et al. 18 
NfL in cerebrospinal fluid

Primary progressive MS
Norgren et al. 20 Teunissen et al. 5 Romme et al. 14 Kuhle et al. 7 Axelsson et al. 21 Trentini et al. 22 Disanto et al. 18 MS: multiple sclerosis; CSF: cerebrospinal fluid.
(RRMS) and controls, 13, 21 indicating a less pronounced effect of these compounds in SPMS and PPMS.
In RRMS, several studies reported relatively strong correlations of CSF NfL with contrast-enhancing lesions (CEL) 5, 24, 33, 34 (Table 3 ) and T2 lesion load, 5, 24, 28, 33, 34 and also with T1 hypointense lesions. 24, 33 Normalized brain volume was correlated with CSF NfL in a study including 36 RRMS patients (r = −0.41, p = 0.014). 28 Interestingly, in 25 RRMS patients switching from no or first line therapies to natalizumab baseline (before switch), NfL levels predicted the amount of brain atrophy over 3 years (r = −0.564, p = 0.012). 35 In a recent study, the occurrence of new T2 lesions and brain atrophy at 1 and 5 years was highly correlated with baseline CSF NfL levels (percentage brain volume change between baseline and year 5: r = −0.842, p < 0.0001; new T2 lesions at year 5: r = 0.589, p = 0.003). 34 In progressive MS, levels were higher in patients with versus without CEL in 35 progressive MS patients (p = 0.013). 21 In a study involving 12 SPMS and 12 PPMS treated with natalizumab over 1 year, changes in NfL correlated with magnetization transfer ratio (MTR) changes in normal appearing white matter (NAWM; r = −0.73, p = 0.003) and gray matter (GM; r = −0.66, p = 0.001). 32 In 2004, Norgren et al. 20 reported a correlation between NfL and the EDSS score in patients in remission at clinical follow-up of a median of 5 years (r = 0.28, p = 0.03). In total, 95 of 99 of these patients were further followed for a median of 14 years (range = 8-20 years): high baseline NfL levels increased the risk for increased disability as measured by the multiple sclerosis severity score (odds ratio (OR) = 3.2, p = 0.01) and conversion to SPMS (p = 0.03). 36 Trentini et al. 22 found NfL levels in 31 progressive MS patients to be predictive of the annual EDSS increase over a median follow-up of 9 years. 
NfL in peripheral blood
A prerequisite for the practical use of serum NfL (sNfL) as an equally relevant biomarker compared to CSF derived NfL is a well-defined correlation of values between these two compartments. CSF and sNfL levels were highly correlated in 31 RRMS patients (r = 0.62, p = 0.0002) 17 and sNfL levels were consistently higher in CIS and RRMS versus healthy controls. 10 CIS patients with higher sNfL also had higher EDSS scores (p = 0.013), 10 and changes in sNfL were correlated with EDSS change in 42 RRMS patients over 2 years of follow-up (p = 0.009). 31 In the same study, sNfL decreased relative to baseline at month 12 (p = 0.001) and month 24 (p = 0.007) suggesting a potential treatment effect of interferon beta-1a (IFNb-1a) IM. 31 CIS patients with CEL (p = 0.026) and more T2 lesions (p = 0.011) had higher sNfL levels. 10 sNfL correlated with the white matter lesion volume (r = 0.68, p < 0.0001), MTR (r = −0.41, p = 0.029), and mean T1 (r = 0.40, p = 0.034) and T2* relaxation times (r = 0.49, p = 0.007) in NAWM. 17 Interestingly, brain volume decreased more rapidly in patients with high baseline sNfL over the next 12 and 24 months (p = 0.05 at month 12 and p = 0.008 at 24 months) and patients with higher sNfL at baseline or increasing sNfL had more CEL over the study period (p < 0.001, respectively). 31 All three studies used an electrochemiluminescence (ECL)-based assay 37 that has limited accuracy in measuring low levels of NfL.
With the advent of the single-molecule array (Simoa) technology as a digital immunoassay, the sensitivity has significantly improved and now allows accurate quantitation of sNfL levels in healthy controls. 18, [38] [39] [40] [41] Based on this analytical platform, the high correlation of NfL levels in the CSF and in the blood compartment has been confirmed in MS, 18, 19 as well as in other primary neurodegenerative disorders such as progressive supranuclear palsy 42 or mild cognitive impairment/Alzheimer's disease (MCI/AD). 43 Using the Simoa technology, we found sNfL levels were higher in patients with CEL and larger T2 lesion volume. sNfL was independently associated with EDSS (p < 0.001) and the presence of relapses (p < 0.001). sNfL levels were lower under disease-modifying treatment (p = 0.003) and patients with sNfL levels above the 80th, 90th, 95th, 97.5th, and 99th healthy controls-based percentiles were at higher risk of relapses (97.5th percentile: incidence rate ratio = 1.94, 95%CI = 1.21-3.10, p = 0.006) and EDSS worsening (97.5th percentile: OR = 2.41, 95% CI = 1.07-5.42, p = 0.034). 18 Recently, Piehl and colleagues 19 reported reduced plasma NfL levels measured by Simoa technology in 243 patients after 1 (p < 3 × 10 −6 ) and 2 years (p < 9 × 10 −12 ) of starting fingolimod within the Immunomodulation and Multiple Sclerosis Epidemiology (IMSE) study.
NfH in peripheral blood
Several studies used conventional ELISA (enzymelinked immunosorbent assay) assays to determine NfH in CSF and blood samples. We here summarize the findings in serum or plasma. Higher plasma/serum NfH levels were described in acute optic neuritis with higher levels predicting worse visual outcome. 44, 45 After chemotherapy and total body irradiation followed by autologous bone marrow transplantation, serum NfH (sNfH) levels were >100-fold higher 1 month after chemotherapy compared to baseline, and high sNfH levels were associated with sustained disability worsening on EDSS (p < 0.05). 46 In a trial of lamotrigine in SPMS, adherent patients had significantly lower sNfH levels when compared to the nonadherent group (p = 0.043 and p = 0.023). Patients with detectable sNfH performed worse in the 25 foot walk (p < 0.001), the 9-hole peg test (p < 0.001) and had higher EDSS scores and lower MTR. 47 sNfH levels were significantly higher in SPMS than healthy controls (p = 0.011), CIS (p = 0.041) and RRMS (p = 0.048) with no significant differences between the other groups. 48 Finally, in a recent longitudinal study in 42 early RRMS, patients with higher sNfH at baseline or increasing sNfH also had higher numbers of CEL (p < 0.001 and p = 0.009). 31 For now, it is unclear whether NfH and NfL are strictly correlated in MS, or whether different stages and states of disease may be reflected by a higher release of one marker over the other.
Other potential biomarker candidates
Despite the large number of candidate molecular proteinic biomarkers proposed in neurological disease, very few of them have been rigorously validated for use in clinical practice or trials. For MS, exploratory candidate biomarkers (as recently classified in Comabella and Montalban 49 ) include gene expression regulating microRNAs, transcription factor TOB1, 50 auto-antibodies (e.g. against NfL 49,51 ), and numerous cytokines and structural CNS-proteins.
For most, further steps needed would be technical validation and definition of clinical usefulness, including what unmet diagnostic need will be covered. We therefore restrict our review to markers that may match this profile in the near future.
Matrix metalloproteinase-9 (MMP-9) is involved in myelin breakdown, release of proinflammatory cytokines, and axonal damage ( Table 4 ). Serum and CSF levels are increased during relapse and are associated with MRI disease activity. 52, 53, 58, 92 MMP-9 is one of the most sensitive markers of inflammation in general, including for drug response in CSF. 59 Because MMP-9 is produced by many cells inside and outside of the CNS and is released in non-neurological inflammatory diseases, proof of its utility in trials or individual clinical use is still pending. Chemokine ligand 13 (CXCL13) is increased during active MS (CSF and serum), is a B-cell chemoattractant that interacts with CXCR5 on B-cells, and is required for the development of B-cell follicles and potentially tertiary (meningeal) lymphoid structures (Table 4) . 64, 66, 67, 93, 94 Higher levels of CXCL13 also predict conversion from CIS to MS. 66, 68, 69, 95 Within different stages of MS, CSF CXCL13 was highest during relapses of RRMS, but was higher than in controls during all stages. 67 Furthermore, CXCL13 CSF levels drop drastically under natalizumab therapy. 59 Glial fibrillary acidic protein (GFAP, in CSF) is an astrocytic cytoskeletal component and belongs to the intermediate filaments (Table 4 ). It is released after astrocyte damage and astrogliosis, and increased levels in MS have been described by several groups. 12, 20, 70 Increased concentrations are associated with higher disability and disease progression. 71, 72, 79 Brain-derived neurotrophic factor (BDNF, in serum and plasma) is a neurotrophic factor not only secreted by neurons but also by immune cells with roles in CNS neurogenesis, neuroprotection, and neuroregeneration (Table 4 ). Concentrations have been reported to be increased in patients during relapses. 76, 77, 96 Chitinase-3-like 1 (CHI3L1 or YKL-40, in CSF and serum) is a glial activation marker that is not only secreted mainly by activated macrophages but also expressed by smooth muscle cells, airway epithelia, and chondrocytes 80 (Table 4 ). Concentrations are increased in patients with CIS who later convert to MS. [80] [81] [82] Interestingly, high CSF CHI3L1 levels were also associated with earlier disability progression (reaching EDSS 3 and 6). 79, 80 Finally, osteopontin (in CSF, serum, and plasma) has pleiotropic roles, including inflammation, cell-mediated immunity, and cell survival. It is an early activation marker on T-cells with a role in T-cell co-stimulation and IFNγ expression 84 (Table 4 ). Concentrations are increased in RRMS during clinical relapses and correlated to disease severity and relapse rate. 49, [85] [86] [87] [88] [89] An association with disease severity and osteopontin measurements in peripheral blood was, however, not found in two other studies. 91, 97 Degradation of extracellular matrix and junctional proteins to increase the blood brain barrier endothelial permeability and involved in myelin breakdown, release of proinflammatory cytokines, and axonal damage. Regulated by TIMPs.
Increased in CSF/serum during relapses and correlated with MS disease activity. [52] [53] [54] [55] [56] [57] In serum shown to decrease following IFNb and natalizumab treatment and predict new active lesions. 52, [58] [59] [60] [61] [62] [63] Chemokine ligand 13 (CXCL13) Attracts CXCR5 expressing B lymphocytes and less T-cells and macrophages into the CNS.
Upregulated in active MS lesions and CSF levels correlate with intrathecal
IgG production and CSF cell number. 64 Increased in CSF of RRMS 9 and SPMS; 14,64,65 conflicting results in PPMS; 14, 66 predictive of conversion to RRMS in CIS. 67, 68 Reduced in CSF by natalizumab in progressive MS 59 and by methylprednisolone and natalizumab in RRMS. 66 Elevated levels in CSF associated with disease activity and unfavorable prognosis. 67 Serum levels increased in patients with active MRI. IFNb or GA did not affect these levels; 69 no difference in comparison with controls in plasma. 9 Increased in CSF in RRMS 70 and especially PMS and correlates with disease severity and disease progression. 12, 20, 71, 72 No difference in CSF between RMS and healthy controls. 9, 20 Highly increased in CSF 73 and in serum 74, 75 in NMO.
BDNF
Neurotrophin with suggested role in preventing neural death secreted by neurons and different inflammatory cells (lymphocytes, monocytes) and platelets.
Higher levels in CSF of RRMS in remission compared to SPMS and healthy controls. Higher in RRMS with enhancing lesions and lower levels in SPMS with EDSS progression in previous 6 months. 76 Higher serum levels in relapse versus remission. 76 Lower plasma levels in RRMS than healthy controls and higher levels in relapse than remission. 77 Higher plasma levels in natalizumab-treated RRMS and SPMS versus untreated patients and lower levels compared to healthy controls. 78 
Chitinase-3-like 1 (CHI3L1 or YKL-40)
Member of the chitinase-like glycoprotein family predominantly produced by reactive astrocytes and microglia, and also smooth muscle cells, airway epithelia, and chondrocytes. Physiological role unknown, hypothesized to be involved in tissue remodeling during inflammation.
Higher CSF levels in CIS converting to RRMS; association with active MRI lesions, number of T2 lesions, and disability progression. [79] [80] [81] [82] Higher CSF levels in RRMS compared to healthy controls; 9, 16 higher CSF levels in MRI active RRMS and SPMS when compared to healthy controls. 83 Higher CSF and serum levels in CIS, RRMS, and PMS compared to controls and CSF and serum values predicted conversion from CIS to RRMS. 82 CSF levels decreased after fingolimod treatment in RRMS. 29 
Osteopontin
Pleiotropic functions, including roles in acute and chronic inflammation, cellmediated immunity, tissue remodeling, and cell survival (co-stimulates T-cell proliferation, recruitment of macrophages, and T-cells to inflamed sites, role in Th-1 responses).
Abundantly detected transcripts for osteopontin in MS plaques but not control brain. 84 Increased in plasma of RRMS but not PPMS and SPMS; increased in relapse versus remission. 85 Serum levels not associated with relapse disease activity, trend for higher levels in patients with enhancing MRI lesions. 86 Increased in plasma in SPMS 87 and RRMS during relapse and in RRMS and SPMS without disability progression in the previous year. 88 Higher CSF levels in CIS, RRMS, and PPMS than controls. 87, 89 No difference in plasma levels between RRMS and controls, but higher in CSF and significantly reduced after 12 months natalizumab treatment. 90 Increased levels in plasma of RRMS and SPMS with lower levels in patients treated with natalizumab or GA, but no association with disease activity. 91 CSF: cerebrospinal fluid; MS: multiple sclerosis; IFNb: interferon-beta; TIMPs: tissue inhibitors of metalloproteinases; CNS: central nervous system; RRMS: relapsing-remitting MS; SPMS: secondary progressive MS; PPMS: primary progressive MS; CIS: clinically isolated syndrome; MRI: magnetic resonance imaging; GA: glatiramer acetate; GFAP: glial fibrillary acidic protein; PMS: progressive MS; RMS: relapsing MS; NMO: neuromyelitis optica; BDNF: brainderived neurotrophic factor; EDSS: Expanded Disability Status Scale.
Future perspectives
Biofluid markers that accurately reflect specific pathogenic mechanisms of MS or allow to monitor disease activity would be invaluable tools both for individual therapeutic decision-making and to measure drug effects in clinical trials. Apart from IgG-OCB or IgG-index, anti-aquaporin 4 antibodies, anti-drug-antibodies against interferon or natalizumab, and anti-JCV (John Cunningham virus)-antibody titers in the context of progressive multifocal leukoencephalopathy (PML) risk, biomarkers have so far a weak standing in MS. Besides the problems with technical verification and replication, the lack of relation to features of progressive MS, where clinical and MRI measures are of limited value, too, have prevented their establishment. Specifically, ongoing subclinical disease activity related to progression cannot be captured accurately and surfaces clinically only over a long observation period.
The establishment of NfL as measure of ongoing neuronal loss in a routinely accessible body fluid source potentially marks a breakthrough in the field of MS biomarkers. There is consistent evidence that NfL levels in serum and plasma are increased in all stages of MS and correlate with clinical and MRI measures of ongoing disease activity and severity. Moreover, there is an accumulating body of data that NfL levels capture treatment response in all stages of MS and that they appear to be predictive for future disease outcome.
The close correlation of Nf levels in serum/plasma and CSF in numerous studies in MS and in other neurological diseases 17, 18, 19, 37, [98] [99] [100] [101] [102] allows to conclude from blood values on the degree of ongoing neuroaxonal injury in the CNS and to become independent of lumbar puncture. However, NfL levels in serum and plasma are approximately 30-to 70-fold lower than those in CSF, and quantitation close to normal values prerequisites a high-sensitivity measurement platform like Simoa, while ECL immunoassays and more so conventional ELISAs are too insensitive. 41 While NfL measurements seem to mark a common final path of neuroaxonal injury independently of specific causal (inflammatory and non-inflammatory) pathways, the broadening armamentarium of additional highly sensitive assays may shed even more light on patient heterogeneity and mechanisms leading to this damage in future.
There are currently two development steps lacking for NfL to reach potential surrogacy. The normative data base for NfL including for changes in function of physiological rhythms (e.g. diurnal, menstrual), metabolic illnesses, confounding CNS disease and age is insufficient. This situation resembles that of tumor markers, suggesting that mainly longitudinal measurements would be meaningful for interpretation on an individual patient level.
The second limitation for exploring surrogacy is the lack of robust data on the predictive capacity of NfL for the short-and long-term outcome of MS, both with and without therapy, and how they relate to the current MRI-based standard measures. Therefore, correlative data of NfL and standard clinical MRI disease measures from well-documented long-term patient cohorts are needed.
Electrophysiological outcomes
EPs provide information about nerve conduction along central motor and sensory pathways. Because of their very high temporal resolution, they reveal even minor demyelinating/remyelinating processes. The pathways explored by EPs are frequently affected in MS. In progressive MS, one or more modalities are almost invariably affected. 103 Interestingly enough, EPs may reveal dysfunctions even in the absence of evident MRI lesions affecting the tested pathway. 104 Combined multimodal EPs have been reported to correlate with global measures of disability in mixed cohorts of RRMS and progressive MS, 103, 105 as well as in PPMS in cross-sectional 106, 107 and longitudinal evaluations. 107 Unfortunately, studies specifically addressing progressive patients are scarce and involve small samples and in mixed cohorts, with the relapsing-remitting form typically over-represented (for a review, see Hardmeier et al.) . 108 In longitudinal studies, combined EPs were predictive of future medium and long-term disability and, moreover, deterioration of neurophysiological parameters was also observed in the absence of changes of EDSS score, indicating the good responsiveness of EPs. 109 In PPMS, multimodal EPs showed significant changes 6 months before EDSS. 107 The value of individual EP modalities as an outcome measure in phase 2 clinical trials in progressive MS depends on technical and methodological aspects and on the population under study. 109 It is generally accepted that brainstem auditory EPs (BAEPs) have the lowest sensitivity, 103, 108 possibly due to the shortest pathway explored. Visual EPs (VEPs) are more sensitive than optical coherence tomography (OCT) in detecting involvement of the visual pathways in MS. 110 Although useful to quantify improvement after treatment in acute optic neuritis 111 and in chronic demyelination, [112] [113] [114] VEPs display poor cross-sectional and longitudinal correlation with EDSS, a lower rate of progression compared to lower limb motor EPs (MEPs), 109 and lower value in discriminating patients with active disease compared to OCT. 115 The recently developed technique of multifocal VEPs (mfVEPs) seems more sensitive to local optic nerve damage, 116, 117 and more reproducible than standard, full-field VEPs. 118 The high reproducibility of mfVEP amplitudes 119 may improve the value of EPs as a correlate of neuroaxonal damage, as compared to latency, which is considered as better associated with the extent of demyelination. 119 mfVEPs may be a better candidate metric than full-field VEPs to combine with OCT to monitor subclinical myelin and axonal damage in MS because of the good topographic correspondence with OCT findings. 120 Large, multicentre studies are needed in order to qualify their role in proof of concept studies of neuroprotective and remyelinating interventions.
EPs assessing the longest somatosensory and motor pathways are the most frequently abnormal modality in all disease forms, including progressive MS 103, 109 due to their increased likelihood of being involved by demyelinating lesions or as an expression of lengthdependent degenerative process characterizing the progressive phase of the disease. Accordingly, in published reports on mixed-patients cohorts, the best correlations with disability were granted by lower limb somatosensory EPs (SEPs) and MEPs to the lower limb. 103, 109, 121 MEP latency displays the most specific correlation and the highest predictive value for disability progression 122 and sensitivity to change over time. 109 The mismatch between worsening of spinal EPs and unchanged disability may be the expression of nervous system plasticity, at the expense of reduced functional reserve predictive of subsequent EDSS increase. 123 In a small cohort of progressive patients, 124 changes in MEPs over 2 years were mostly related to decrease intracortical inhibition and increased motor threshold for obtaining a motor response, without significant changes in response latency despite worsening of disability. In that study, the upper limb was studied and no information was obtained from the lower limbs, which in progressive disease are the most informative site related to progression of disability. Among the different EP modalities, MEPs, particularly to the lower limb, have the highest significance in discriminating relapsing from progressive disease, 103, 109 pointing to a different spinal cord involvement in the two forms of the disease. 125 Corticospinal delay has been shown to be predictive of response to aminopyridine, which improves conduction along demyelinated axons. 126 Disappearance of lower limb MEPs has been reported to predict disability worsening in patients with progressive MS. 127 However, as absent EP components may prevent their use in clinical trials due to ceiling effects, it is important to further establish the proportion of informative EPs that can be obtained in progressive MS. Absent VEPs can be found in about 30% of SPMS and in 10% of PPMS, 128 suggesting a different involvement of the visual pathways in the two forms of the disease. Similarly, lower limb MEPs were not present in about half of a cohort of 40 progressive patients undergoing intensive neurorehabilitation, while upper limb MEPs were absent only in 12.5% and delayed in 70%. 129 Central conduction time at upper limb SEPs predicted the subsequent extent of improvement in patients undergoing upper limb rehabilitation 130 and cortical plasticity tested on upper limb MEPs predicted recovery from relapse. 131 In cross-sectional studies, upper limb MEPs have been demonstrated to well correlate with upper limb function. 132 These preliminary findings suggest that upper limb may be a better target than the lower limb for clinical trials targeting progressive disease, perhaps not only considering EPs but clinical testing as well, being the upper limb potentially more suitable than the lower limb to demonstrate changes over time and responsiveness to treatment in progressive disease with advanced disability.
Cognitive event-related potentials (ERPs), mainly the P300 component, are significantly correlated with neuropsychological performance, 133, 134 as well as with MRI lesion load. 135 In the latter study, discriminant analysis based on combined MRI and ERPs could classify 79.63% of patients in RR, PP, and SP subgroups. In MS, a good test-retest consistency has been demonstrated for topography. 136 However, the setting for recording cognitive potentials, as well as the most suitable task, needs to be identified and standardized. Moreover, the reproducibility of their latency and their sensitivity to change in progressive MS, in terms of long-term monitoring and responsiveness to treatment, still needs to be determined.
Conclusion
Although fluid biomarkers such as the Nfs and EPs have been rarely used as outcome measures in progressive MS clinical trials, they may have a relevant role in the evaluation of potentially remyelinating and neuroprotective therapies. Large, multicentre studies to validate their roles as potentially informative trial outcomes are needed.
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